Announcements Trials
Browse Landscape

Phase

Phase 3 100Phase 2 89Phase 1 56Phase 1/2 34Phase 4 7Phase 2/3 7Phase NA 2Phase EARLY_PHASE1 2

Status

Completed 2Active not recruiting 2Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 9INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 5Breast 2

Conditions

Stomach Neoplasms 3HER2-positive Gastric Cancer 1HER2-positive Breast Cancer 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 29Carboplatin 28Gemcitabine 27Paclitaxel 26pembrolizumab 24Capecitabine 16Pemetrexed 15Bevacizumab 15Docetaxel 14Oxaliplatin 13Fluorouracil 12Drug Therapy 12Nivolumab 10130-nm albumin-bound paclitaxel 9anlotinib 7Trastuzumab 7Injections 7Rituximab 6atezolizumab 5Temozolomide 5Leucovorin 5Ipilimumab 5venetoclax 4Lenalidomide 4Irinotecan 4Interferon alpha-2 4Folfox protocol 4Dexamethasone 4Albumin-Bound Paclitaxel 4sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × Trastuzumab × Clear all
NCT07413939 2026-05-11

BREnnA

Hoffmann-La Roche

Phase 2/3 Recruiting
650 enrolled
Breast

HER2-positive Breast Cancer

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT05980481 2025-09-29

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

RemeGen Co., Ltd.

Phase 2/3 Active not recruiting
201 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05002127 2025-08-07

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

ALX Oncology Inc.

Phase 2/3 Active not recruiting
127 enrolled
Gastrointestinal

Stomach Neoplasms

NCT04082364 2025-06-08

MAHOGANY

MacroGenics

Phase 2/3 Completed
82 enrolled 22 charts
Gastrointestinal

Stomach Neoplasms

NCT04499924 2025-01-22

MOUNTAINEER-02

Seagen Inc.

Phase 2/3 Completed
17 enrolled 23 charts
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT02213744 2017-01-06

HERMIONE

Merrimack Pharmaceuticals

Phase 2/3 Terminated
113 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡